TScan Therapeutics, Inc. (TCRX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-06) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-04) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-05) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | 8-K (2024-04-17) · 99.1 · 99.2 | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | 8-K (2024-03-06) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Operations and Comprehensive Loss | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses and Other Current Liabilities | ||
| Collaboration and License Agreements | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Loan and Security Agreements | ||
| Nature of Business and Basis of Presentation | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Restructuring | — |
|
| Retirement Plan | — |
|
| Segment Reporting | ||
| Stock Based Compensation | — |
|
| Stockholders' Equity | ||
| Subsequent Event | — |
|
| Summary of Significant Accounting Policies | ||